About Orbion
We're Decoding the
Language of Life
Every protein is a sentence written in twenty letters. Orbion interprets it — and turns that interpretation into the decisions you'd otherwise spend months at the bench making.
Founded 2025 · Berlin, Germany
Our Origin
It Started with Proteins in Orbit
When a protein won't behave, the world's biggest drugmakers do something extraordinary — they fly it to space, where microgravity coaxes cleaner crystals and steadier forms than any lab bench can.
So we asked one question
“Can we do this
on Earth?”
You can't send every target to orbit. But what microgravity reveals is really information — and information can be predicted. So we built Orbion to work it out on the ground.
The Idea
Structure was the breakthrough. The decision is the bottleneck.
AlphaFold gave the world the shape of almost every protein. But a shape doesn't tell you which mutation will hold, which construct will express, or which of a thousand designs is worth the six figures it costs to make. That answer still lives at the bench — months away, one experiment at a time.
Orbion interprets the sequence — what will fold, what will express, what will hold together — and turns that interpretation into the decision you actually have to make. No wet lab required to know where to look first.
Our purpose is simple: move protein engineering from trial-and-error to deliberate design.
Sequence
A string in a twenty-letter alphabet.
Structure
Fold, confidence, topology, pockets.
Function
Modifications, roles, stability, yield.
Decision
The handful of constructs worth making.
Why It Matters
Membrane proteins are where modern medicine happens — and where it stalls.
They are the hardest proteins to express, stabilize, and study — and the ones the next generation of medicines depends on. Getting them to behave in the lab is slow, expensive, and mostly guesswork. That is the wall we exist to move.
of all human proteins are membrane proteins
of drug targets sit in this class
of membrane proteins are targeted by an approved drug
How We Work
What We Value
Impact-Driven
Decoding the language of life helps scientists eliminate disease more effectively. Every model we ship is judged by whether it changes a real decision at the bench — not by how it looks on a leaderboard.
Curious
We are lifelong learners, constantly exploring the frontier of what sequence can tell us. We publish what we find — including where the models fall short — because the science only compounds in the open.
Adaptive
We embrace change, iterate quickly, and refine our approach against real-world data. Every engagement ends in blind, prospective validation on a customer's own targets — the results tell us where to go next.
The Team
Builders at the Edge of Biology and AI
A small team with a background building products across healthcare, data, and machine learning — now pointed at the hardest interpretation problem in biology.
Aniruddh Goteti
Co-Founder
Aniruddh works at the frontier of what protein intelligence can become. He's drawn to the deepest layers of the problem — from generative AI to the quantum and physics questions most of the field hasn't reached yet — and pushes Orbion toward research others still consider too early. That reach is paired with an insistence on rigor: he holds the work to a single conviction — that a protein's behavior can be read before it's ever made.
LinkedIn
Çağlar Bozkurt
Co-Founder
Çağlar works at the frontier of how that science reaches the world. He's spent his career on a single conviction — that a breakthrough matters only in the hands of the people doing the work — and he's building Orbion to give every protein scientist the leverage that once belonged to the largest labs. Close to the researchers who use it and candid about what it can and can't yet do, he holds to one idea: trust is earned by being useful before it's impressive.
LinkedIn
Dr. Evangelia Nathanail
Science Lead
Structural biologist with a PhD from the Max Delbrück Center and postgraduate training in biochemistry at Oxford. A DAAD scholar at Freie Universität Berlin and a Zia Fellow, she is an expert in X-ray crystallography — and holds every Orbion prediction to the standard of the experimental literature.
LinkedIn
Dr. Dennis Kwiatkowski
Business Advisor
A biochemist turned strategist. He earned his PhD at Charité Berlin, moved through Scitaris, and now consults at Temedica on portfolio prioritization and technical due diligence across oncology and metabolic disease. He connects Orbion to the people building the next generation of medicines.
LinkedIn
Come Decode It With Us
Bring your hardest target and watch the predictions land against your own data — or explore the models we've put in the open.